Andrea S. Blevins Primeau, PhD, MBA

A single-arm cohort study sought to determine the efficacy of adding samuraciclib to treatment for ER-positive and/or PGR-positive, HER2-negative breast cancer.

An analysis of patients in the INSEMA trial sought to determine the impact of no SLNB vs SLNB and SLNB alone vs SLNB with ALND on quality of life for patients with breast cancer.

Monitoring bESR1mut enabled optimization of the endocrine therapy used with a CDK4/6 inhibitor.

An analysis evaluated outcomes for patients with breast cancer who were treated with a modern approach compared with a historical standard approach.

Palbociclib added to adjuvant endocrine therapy failed to improve iDFS.

The delay in clip placement was associated with significant anxiety among the patients who were interviewed.